Park, James H.
Feroze, Abdullah H. http://orcid.org/0000-0002-7761-6765
Emerson, Samuel N.
Mihalas, Anca B.
Keene, C. Dirk http://orcid.org/0000-0002-5291-1469
Cimino, Patrick J. http://orcid.org/0000-0003-0441-4502
de Lomana, Adrian Lopez Garcia
Kannan, Kavya
Wu, Wei-Ju
Turkarslan, Serdar
Baliga, Nitin S. http://orcid.org/0000-0001-9157-5974
Patel, Anoop P. http://orcid.org/0000-0001-7078-9535
Funding for this research was provided by:
Burroughs Wellcome Career Award for Medical Scientists Discovery Grant from the Kuni Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32 CA247445-01)
University of Washington Ojemann Family Neurosurgery Research Fund
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R25N2079200)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI141953)
NSF | BIO | Division of Biological Infrastructure (NSF1565166)
Institute for Systems Biology Funding Washington Research Foundation Funding
Article History
Received: 1 February 2021
Accepted: 22 June 2022
First Online: 8 August 2022
Competing interests
: N.S.B. is a co-founder and member of the Board of Directors of Sygnomics, Inc., which will commercialize the SYGNAL technology. The terms of this arrangement have been reviewed and approved by ISB in accordance with its conflict of interest policy. A.P.P. is a consultant for and has an equity interest in Sygnomics, Inc.